X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DIVIS LABORATORIES - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DIVIS LABORATORIES NOVARTIS/
DIVIS LABORATORIES
 
P/E (TTM) x 301.8 33.1 910.8% View Chart
P/BV x 25.7 5.4 478.1% View Chart
Dividend Yield % 1.4 0.9 154.0%  

Financials

 NOVARTIS   DIVIS LABORATORIES
EQUITY SHARE DATA
    NOVARTIS
Mar-17
DIVIS LABORATORIES
Mar-17
NOVARTIS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8551,222 70.0%   
Low Rs666784 84.9%   
Sales per share (Unadj.) Rs219.0153.1 143.1%  
Earnings per share (Unadj.) Rs19.139.9 47.8%  
Cash flow per share (Unadj.) Rs20.344.6 45.5%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.31.0 131.9%  
Book value per share (Unadj.) Rs307.0201.8 152.1%  
Shares outstanding (eoy) m29.96265.47 11.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.56.6 53.0%   
Avg P/E ratio x39.825.1 158.5%  
P/CF ratio (eoy) x37.522.5 166.5%  
Price / Book Value ratio x2.55.0 49.8%  
Dividend payout %52.425.0 209.1%   
Avg Mkt Cap Rs m22,779266,266 8.6%   
No. of employees `0000.79.7 6.9%   
Total wages/salary Rs m1,3934,687 29.7%   
Avg. sales/employee Rs Th9,736.24,175.0 233.2%   
Avg. wages/employee Rs Th2,066.8481.5 429.2%   
Avg. net profit/employee Rs Th849.01,089.3 77.9%   
INCOME DATA
Net Sales Rs m6,56240,643 16.1%  
Other income Rs m702749 93.7%   
Total revenues Rs m7,26441,392 17.5%   
Gross profit Rs m25914,460 1.8%  
Depreciation Rs m361,233 2.9%   
Interest Rs m723 31.9%   
Profit before tax Rs m91713,953 6.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3453,349 10.3%   
Profit after tax Rs m57210,604 5.4%  
Gross profit margin %3.935.6 11.1%  
Effective tax rate %37.624.0 156.7%   
Net profit margin %8.726.1 33.4%  
BALANCE SHEET DATA
Current assets Rs m9,73140,105 24.3%   
Current liabilities Rs m1,8306,595 27.8%   
Net working cap to sales %120.482.5 146.0%  
Current ratio x5.36.1 87.4%  
Inventory Days Days49119 41.1%  
Debtors Days Days2581 31.2%  
Net fixed assets Rs m5719,995 0.3%   
Share capital Rs m141531 26.5%   
"Free" reserves Rs m9,05653,043 17.1%   
Net worth Rs m9,19653,574 17.2%   
Long term debt Rs m00-   
Total assets Rs m11,49961,585 18.7%  
Interest coverage x128.4618.4 20.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.7 86.5%   
Return on assets %5.017.3 29.2%  
Return on equity %6.219.8 31.4%  
Return on capital %10.126.1 38.5%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m12935,384 0.4%   
Fx outflow Rs m1,73410,399 16.7%   
Net fx Rs m-1,60524,985 -6.4%   
CASH FLOW
From Operations Rs m-38011,493 -3.3%  
From Investments Rs m4,208-11,372 -37.0%  
From Financial Activity Rs m-3,318-93 3,563.9%  
Net Cashflow Rs m51028 1,796.1%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.8 16.9%  
FIIs % 1.6 19.0 8.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.2 125.0%  
Shareholders   41,647 31,796 131.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Pharma & Realty Stocks Gain(09:30 am)

Asian share markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.1%. The Shanghai Composite is trading down by 1.1%.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 20, 2018 10:53 AM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS